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ABSTRACT Bordetella pertussis causes the disease whooping cough through coordi-
nated control of virulence factors by the Bordetella virulence gene system. Microar-
rays and, more recently, RNA sequencing (RNA-seq) have been used to describe in
vitro gene expression profiles of B. pertussis and other pathogens. In previous stud-
ies, we have analyzed the in vitro gene expression profiles of B. pertussis, and we hy-
pothesize that the infection transcriptome profile in vivo is significantly different
from that under laboratory growth conditions. To study the infection transcriptome
of B. pertussis, we developed a simple filtration technique for isolation of bacteria
from infected lungs. The work flow involves filtering the bacteria out of the lung ho-
mogenate using a 5-m-pore-size syringe filter. The captured bacteria are then lysed
to isolate RNA for Illumina library preparation and RNA-seq analysis. Upon compar-
ing the in vitro and in vivo gene expression profiles, we identified 351 and 255
genes as activated and repressed, respectively, during murine lung infection. As ex-
pected, numerous genes associated with virulent-phase growth were activated in
the murine host, including pertussis toxin (PT), the PT secretion apparatus, and the
type III secretion system. A significant number of genes encoding iron acquisition
and heme uptake proteins were highly expressed during infection, supporting iron
acquisition as critical for B. pertussis survival in vivo. Numerous metabolic genes were
repressed during infection. Overall, these data shed light on the gene expression
profile of B. pertussis during infection, and this method will facilitate efforts to un-
derstand how this pathogen causes infection.
IMPORTANCE In vitro growth conditions for bacteria do not fully recapitulate the
host environment. RNA sequencing transcriptome analysis allows for the character-
ization of the infection gene expression profiles of pathogens in complex environ-
ments. Isolation of the pathogen from infected tissues is critical because of the large
amounts of host RNA present in crude lysates of infected organs. A filtration method
was developed that enabled enrichment of the pathogen RNA for RNA-seq analysis.
The resulting data describe the “infection transcriptome” of B. pertussis in the murine
lung. This strategy can be utilized for pathogens in other hosts and, thus, expand
our knowledge of what bacteria express during infection.
KEYWORDS Bordetella pertussis, in vivo RNA sequencing, infection transcriptome,
pertussis, transcriptomics, whooping cough
Bordetella pertussis is a bacterial respiratory pathogen and the causative agent ofwhooping cough, otherwise known as pertussis. While whooping cough is a
vaccine-preventable disease, the number of cases has risen during the past decade (1).
Reemergence of pertussis is a multifactorial problem that highlights the need to
redesign and improve current vaccination strategies. Whole-cell vaccines (WCV), made
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of formalin-inactivated bacteria, were first introduced in the 1940s in the United States.
Following implementation of the WCV, efforts by numerous research teams led to the
identification of B. pertussis major virulence factors, such as the adenylate cyclase toxin
(ACT), pertussis toxin (PT) (2), and others. The identification of B. pertussis major
virulence factors also included the discovery of the global regulatory system of viru-
lence genes (Bordetella virulence gene [Bvg] system) (3) and of important surface
adhesins such as filamentous hemagglutinin (FHA) (4), fimbriae (FIM) (5), and pertactin
(PRN) (6). The DTaP acellular vaccine is composed of PT, FHA, and PRN antigens (7),
whereas the Tdap formulation includes the FIM antigen. Since the implementation of
the acellular vaccination schedule, an alarming rise in pertussis cases have been
observed. Due to the reemergence of pertussis (8, 9), there is a need to develop a
third-generation pertussis vaccine. We hypothesize that achieving a deeper under-
standing of B. pertussis during infection of model organisms will aid in the identification
of new protective antigens.
Microarrays have been utilized to study B. pertussis gene expression in regard to the
Bvg system (10, 11), epidemic strains (12), ptxP3 linage strains (13), the iron starvation
response (14), the RisA regulon (15), Hfq-directed virulence genes (16), and others.
Many studies performed in Bordetella bronchiseptica have detailed the gene expression
of clinical and lab-adapted strains in response to different growth conditions (17–22).
All of the aforementioned studies have significantly enhanced our knowledge about
genetic regulation in Bordetella. For example, microarray analysis defined the list of
virulence-activated genes (VAGs) and virulence-repressed genes (VRGs), which are
controlled by BvgAS (11). The BvgAS master regulatory system controls three phases of
B. pertussis: the Bvg, Bvgi, and Bvg phases. Virulence-repressed genes are expressed
during the Bvg phase. The Bvgi phase occurs when the BvgAS system is partially
active, and it controls the expression of genes such as fhaB, fim, and bvgAS. In the Bvg
phase, BvgAS is fully active and controls expression of virulence-activated genes such
as PT and ACT and genes involved in the type III secretion system (23).
As RNA sequencing (RNA-seq) developed and became more readily available to the
research community, it was used to further study the importance of gene expression
and regulation in Bordetella. For example, Ahuja et al. used RNA-seq transcriptomic
analysis to characterize the genetic regulation of the type III secretion system (24). We
followed the work of Ahuja et al. and characterized the role of the RpoE sigma factor
in the global gene expression profile of B. pertussis and observed inverse regulation of
pertussis and adenylate cyclase toxins (25), suggesting the presence of non-BvgAS
regulatory mechanisms. Recently, Moon et al. also employed RNA-seq analysis to more
precisely define the BvgAS regulon (26). Furthermore, Lesne et al. teased out the
distinct virulence ranges of B. pertussis governed by this system during murine respi-
ratory tract infection using bvgS mutants (27). After identifying the unique infection
profiles of each strain, they performed in vitro RNA-seq to characterize the effects of the
mutations in bvgS and how they affect downstream gene expression (27). While in vitro
RNA-seq analysis provides important insights about regulation of virulence, only one
study has been performed to determine what B. pertussis expresses in the host (28). van
Beek et al. used microarrays to study the in vivo gene expression of B. pertussis in the
murine airway (28). Interestingly, van Beek et al. identified several Bvg repressed genes
that were highly expressed in the murine host. The study also detailed that 30% of the
genome was differentially expressed in a comparison between in vitro and in vivo
conditions (28).
We aimed to develop a robust RNA-seq methodology for gene expression analysis
of B. pertussis in the murine host in order to describe the infection transcriptome of this
pathogen. We have previously performed dual RNA-seq of Pseudomonas aeruginosa in
the murine lung (29). Dual RNA-seq characterizes both the host and pathogen tran-
scriptomes simultaneously. When we attempted to perform dual RNA-seq with B.
pertussis, we identified an insufficient number of reads, and it was not possible to
precisely characterize the bacterial pathogen’s in vivo transcriptome (30). In this study,
we describe a simple filtration method that allowed us to isolate bacteria to facilitate
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characterization of the in vivo transcriptome of B. pertussis by RNA-seq. The in vivo gene
expression profile of B. pertussis did not mimic a known virulence gene expression
profile as precisely as expected. Genes encoding proteins involved in multiple path-
ways of iron acquisition were highly expressed in vivo, highlighting the need of the
pathogen to obtain iron during infection. Overall results from this study suggest that
additional factors, independent from the Bordetella virulence gene system, are involved
in the pathogenesis and survival of B. pertussis during infection. In addition, the
technical advances described here for bacterial isolation from complex tissues will
facilitate the design of future strategies to characterize gene expression of B. pertussis
and other pathogens during infection.
RESULTS
Developing a protocol for in vivo transcriptomic analysis of B. pertussis with
RNA-seq. Our previous studies with the respiratory pathogen P. aeruginosa demon-
strated the feasibility of sequencing both bacterial and pathogen RNAs during infection
(29). However, that study also highlighted the need to have high bacterial loads (108 to
109 CFU/organ) to obtain sufficient RNA for purification and analysis. We initially
attempted to perform RNA-seq of B. pertussis infecting the trachea of outbred CD1
mice; however, those attempts resulted in insufficient bacterial reads for transcriptomic
analysis (data not shown). We then identified the NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)
mouse as a highly susceptible strain due to a lack of mature lymphocytes caused by a
scid mutation in the DNA repair complex protein Prkdc and a mutation in the
interleukin-2 (IL-2) receptor common gamma chain, causing a deficiency in functional
NK cells. Consequently, the NSG mouse also harbors defective macrophages and
dendritic cells, with only neutrophils and monocytes unaffected by the mutations. With
this in mind, we aimed to use the high bacterial burden in NSG mice to facilitate
RNA-seq of infected murine lung (30). However, we were able to map only approxi-
mately 15,000 reads per 100 million to the B. pertussis genome (30). Despite the
limitations of that data set, we observed that the alcaligin siderophore biosynthesis
genes were highly expressed by B. pertussis infecting the NSG mouse lung (30).
Furthermore, we saw that most reads mapped to fhaB, which encodes FHA, suggesting
that this gene could be highly expressed during infection. In our previous study of the
RpoE transcriptome in vitro, we observed that fhaB is one of the most abundant
transcripts in B. pertussis (25). These data encouraged us to continue to refine and
develop the in vivo RNA-seq work flow and methods. In order to maximize removal of
host RNA, we used the small size of the bacterium as a means to separate it from
the host cells. B. pertussis is approximately 1 m in length by 0.5 m in width
(Fig. 1). Using in vitro-grown cultures, we determined that 5-m-pore-size syringe
FIG 1 Experimental procedure for the isolation of bacterial RNA from infected tissue. Infected lungs were homogenized with a Dounce glass homogenizer, and
the lung homogenate was filtered through a 70-m-pore-size cell strainer to remove tissue debris. The strained homogenate was pushed through a
5-m-pore-size syringe filter to exclude eukaryotic cells and capture the bacteria in the filtrate. The captured bacteria were pelleted by centrifugation, and the
contaminating murine RNA (due to cell lysis) was removed. Once supernatant containing contaminating RNA was removed, the bacterial pellet was
resuspended in RNAprotect to stabilize the bacterial cells until RNAsnap isolation.
In Vivo RNA-seq Analysis of B. pertussis
March/April 2019 Volume 4 Issue 2 e00154-19 msphere.asm.org 3
 o
n
 M
ay 21, 2020 by guest
http://m
sphere.asm
.org/
D
ow
nloaded from
 
filters (Minisart; Sartorius) allowed us to collect 50% of the viable bacteria in one
step (Fig. 2A and B).
Isolation and qRT-PCR analysis of B. pertussis from infected murine respiratory
tissues. We next aimed to harvest B. pertussis from infected NSG lungs at 3 days
postinfection using the 5-m-pore-size syringe filtration. The lungs were homogenized
and plated on Bordet-Gengou (BG) agar to determine the bacterial burden (Fig. 2A). The
rest of the homogenate was then filtered through a 70-m-pore-size cell strainer; the
flowthrough was pushed through a 5-m-pore-size syringe filter and collected in a
1.5-ml tube (Fig. 2B). An aliquot of the filtrate was then plated to determine the number
of viable B. pertussis bacteria that passed through the filter. The filtration allowed for
isolation of 50% of the viable bacteria from the infected lungs (data not shown) (30).
To confirm that the filtration method allowed for detection of bacterial transcripts, we
performed quantitative reverse transcription-PCR (qRT-PCR) analysis on B. pertussis RNA
samples from in vitro cultures grown in Stainer-Scholte liquid medium (SSM) and from
B. pertussis-infected NSG lung (Fig. 2C). We observed increased cya and ptx gene
expression in bacteria for all of our NSG mice compared to levels in bacteria grown in
vitro (Fig. 2C). Expression of fhaB, the major adhesin, was decreased in vivo compared
to the level in vitro. The genes cya and ptx are classified as class 2 Bvg system genes
(23), whereas fhaB is a class I gene. Class I genes are usually expressed at different
phases than class II genes, which could explain why cya, ptx, and fhaB are differentially
expressed in these samples. BP2497 was more highly expressed in vitro than in vivo
(Fig. 2C).
In vivo RNA-seq analysis of B. pertussis infecting the murine lung. Libraries were
generated, and Illumina sequencing was performed on B. pertussis in vitro (SSM broth)
and in vivo (filtered NSG mouse lung) RNA samples. As expected, the in vitro samples
resulted in mapping of more than 90% of the reads generated. We were able to map,
on average, 948,281 2- by 150-bp reads per biological sample, resulting in 1% of the
reads corresponding to the pathogen. We obtained 71-fold more RNA mapping with
our filtration method than in our initial attempts to perform dual sequencing on B.
pertussis infecting the NSG lung (without filtration) (30). Overall, approximately 1
million reads from each in vivo sample mapped to the reference genome. Reads
mapped to 94% of the genes on the Tohama I reference genome, giving sufficient data
to describe the transcriptome. With this read depth, we observed that 83% of the genes
FIG 2 Isolation of B. pertussis and qRT-PCR analysis from infected NSG mouse lungs. NSG mice were infected by
intranasal administration of B. pertussis strain UT25. At 3 days postinfection, the nasal wash, trachea, and lung were
collected, and the numbers of input and output bacteria (postfiltration) were quantified. (A) Bacterial load in each
tissue after homogenization. (B) Number of bacteria recovered from each tissue after implementing the filtration
strategy. (C) qRT-PCR analysis was performed on B. pertussis strain UT25 grown in SSM broth and compared to RNA
from the B. pertussis isolated from NSG lungs by the filtration protocol. Fold change in gene expression levels
between in vivo and in vitro growth conditions is shown. Data are from three biological replicates with three
technical replicates each. Standard deviations were calculated from variations between biological replicates and
compared using a t test (*, P 0.05; ***, P 0.001).
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of B. pertussis were expressed in vitro and that 89% of the genes were expressed in vivo.
These numbers are similar to those obtained in our previous studies with the pathogen
P. aeruginosa, for which we detected the expression of 98.2% of the genes in the lung
during infection (29). Due to the large difference in the total numbers of mapped reads
between in vitro and in vivo samples, we down-sampled the in vitro reads to 1 million
to reduce the chances of overestimation errors generated by comparison of large to
small numbers of reads. Down-sampling the reads resulted in the same ratios of reads
from one gene to the next and allowed for a more appropriate analysis with less
saturation effects due to the excess data depth of the in vitro samples.
In vivo expression of known virulence-associated genes and virulence-
repressed genes. We observed that the changes in the expression levels of 606 genes
were statistically significant when in vitro and in vivo conditions were compared
(Fig. 3A; see also Table S1 in the supplemental material). Overall, 351 genes were
significantly activated, 255 genes were significantly repressed, and expression levels of
3,250 genes were not statistically changed between the in vivo and in vitro conditions
(Fig. 3A). To understand the function of the genes with significant changes in expres-
sion, we separated them according to the subcellular localization of the proteins they
encode (Fig. 3B). We observed that the products of the majority of genes up- and
downregulated in vivo were predicted to be localized either in the cytoplasm or
associated with the cytoplasmic membrane.
The Bordetella virulence gene system (BvgAS) controls expression of most of the
virulence factors of B. pertussis. Based on the assumption that virulence genes should
be activated in vivo, we classified them according to the predicted Bvg class they are
associated with. Genes controlled by the BvgA transcription factor are referred to as
virulence-activated genes (VAGs) or virulence-repressed genes (VAGs). In our study, we
designated genes VAGs and VAGs according to an RNA-seq study on the Bvg regulon
in B. pertussis performed by Moon et al. (26). Interestingly, we did not observe an
absolute correlation between VAGs and VAGs in vivo (Fig. 3C); in fact, there was very
little correlation observed. We predicted that most virulence-activated genes would be
activated and that most virulence-repressed genes would be repressed in vivo com-
pared to their expression under in vitro conditions. On the contrary, we observed that
genes designated as activated during virulence were repressed in vivo and vice versa
(Fig. 3C and 4). From these data, we hypothesize that the bacteria harvested from the
lung for this study could be in several virulence phases but that our en masse analysis
is not capable of distinguishing the individual phases. Future studies with single-cell
analysis or protocols with lower numbers of bacteria may be able to tease out these
differences.
Systems-based analysis of differentially expressed genes. We used Gene Ontol-
ogy (GO) term and STRING analysis to group genes of related functions and plotted
FIG 3 Systemic analysis of genes differentially expressed between in vivo and in vitro growth conditions of B. pertussis. (A) Total
number of genes statistically activated or repressed in a comparison of B. pertussis growing in SSM (in vitro) to B. pertussis growing
in NSG mice. (B) Predicted cellular localization of differentially expressed genes, according to the color scheme of panel A. (C)
Numbers of virulence-activated genes (VAGs) and virulence-repressed genes (VRGs) in vivo compared to numbers in vitro revealed
low correlation with Bvg designations. B. pertussis VAGs and VRGs were determined based on the study performed by Moon et
al. (26).
In Vivo RNA-seq Analysis of B. pertussis
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expression differences within a heat map (Fig. 5). In the heat map visualization, gene
expression data are represented by the average number of reads per kilobase million
(RPKM) for each biological sample. The heat map is composed of a 24-color scale, with
each color representing a range of RPKM values evenly distributed across the total
represented data set of expression values. To generate the color map, we divided each
color across a range based on the number of total data points. This allowed for more
distinct visualization for data ranges with more total data points. Four groups of genes
of interest were activated in vivo, i.e., iron acquisition, type III secretion system, pertussis
toxin, and secretion, as well as several key virulence genes (Fig. 5A). We observed that
genes involved in cellular respiration, cell division, cell wall synthesis, and sulfur
metabolism were repressed in vivo. Since genes involved in growth of B. pertussis were
repressed in vivo, we hypothesize that the bacteria were growing more slowly in vivo
than under in vitro growth conditions. Alternatively, in vivo metabolism may be altered
by nutrient availably. Also, it could be hypothesized that in vivo growth is a combina-
tion of slower growth and altered metabolism. Interestingly, we observed that the fhaB
gene encoding filamentous hemagglutinin was also repressed in vivo compared to its
expression in vitro (Fig. 5B). We also observed lower in vivo expression of fhaB by
qRT-PCR (Fig. 2C).
In vivo B. pertussis activates expression of iron acquisition genes. B. pertussis is
known to sequester both iron and heme using nonredundant systems to support its
need for iron during infection. B. pertussis uses both its own siderophore alcaligin and
the xenosiderophores enterobactin (31), ferrichrome, and desferrioxamine B (32) pro-
duced by other bacterial species. Alcaligin is synthesized by various enzymes encoded
by the alcABCDE operon and is exported by the permease AlcS (Fig. 6A). Once outside
the cell, alcaligin binds iron. Ferric alcaligin interacts with, and is taken up by, the
TonB-dependent outer membrane receptor FauA. B. pertussis also encodes the BfeA
receptor that interacts with BfeB to take up xenosiderophores (Fig. 6B). Heme binds to
the receptor BhuR on the surface of B. pertussis. The heme is then transported into the
periplasm by a TonB-dependent mechanism, and the proteins BhuU and BhuV trans-
locate heme to the cytoplasm (Fig. 6C). Several studies have shown that B. pertussis
relies on the iron uptake systems for growth in vivo (33) and that iron starvation is a key
host environmental cue for adaptation and virulence (34, 35). Interestingly, we ob-
FIG 4 Volcano plot indicating B. pertussis gene expression in the infected lung compared to expression in vitro.
Yellow denotes significant activated genes, and green indicates significant repressed genes. Virulence-activated
genes (VAGs) are denoted by triangles and virulence-repressed genes (VRGs) are denoted by squares. Genes that
are independent of the BvgAS system are shown with circles. B. pertussis VAGs and VRGs were determined based
on the study performed by Moon et al. (26).
Wong et al.
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served that iron acquisition genes were highly activated in vivo (Fig. 6). Specifically,
genes involved in alcaligin siderophore biosynthesis (alcABCDER), alcaligin siderophore
receptor (fauA), xenosiderophore receptor (bfeA), and heme acquisition proteins (bhuR,
hurI, hurR, bhuT, and bhuS) were significantly upregulated in vivo (Fig. 5 and 6D). These
data support the idea that acquisition of iron is important for infection of B. pertussis in
the host.
FIG 5 Heat map visualization of in vivo-activated and -repressed genes organized by function. The average number per million mapped reads
(RPKM) is denoted by the color scale. The maximum value of the scale is set at 1,500 RPKM (red), and the minimum is at 0 RPKM (black). The
distribution of the color scale of 24 colors is divided by the total number of data points per range. The Erlenmeyer flask represents in vitro
conditions, and the mouse represents in vivo conditions. (A) Activated groups in vivo compared to expression in vitro include iron acquisition, type
III secretion system (T3SS), pertussis toxin, and other virulence factors. (B) Repressed groups in vivo compared to expression in vitro include
cysteine and sulfur, cell division, iron, and virulence factors. The average fold change in vivo compared to that in vitro is noted on the right of
the gene name, and all genes shown were statistically significant.
In Vivo RNA-seq Analysis of B. pertussis
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DISCUSSION
The goal of this study was to characterize the in vivo transcriptome of B. pertussis
during infection of the murine lung. qRT-PCR and microarray technologies have pro-
vided high-quality data concerning the gene expression of B. pertussis under various
conditions, and microarrays have also been used to study the in vivo transcriptome (28).
In this study, we aimed to build upon our past RNA-seq analysis (29, 30, 36) and to
develop a protocol for isolating bacteria from the infected murine lung to perform
RNA-seq and better understand the gene expression profile in the host. Using filtration,
we were able to separate bacteria from the infected lung cell suspension. A total of 606
genes were differentially expressed in vivo versus expression in vitro. Remarkably, our
analysis indicates that 84% of genes encoded in the B. pertussis genome are expressed
at similar levels in vitro and in vivo in our comparison of growth in SSM broth and that
in the mouse lung environment. These data are surprising as they indicate that more
genes are expressed at similar levels under both conditions than are significantly
differently expressed, suggesting that growth in SSM broth results in gene expression
similar to that in vivo. In other studies, we have also compared growth in SSM to that
in BG agar, and principal-component analysis indicates that SSM and BG agar induce
distinct expression profiles (unpublished data). The genes most highly activated in vivo
encode components of the iron and heme acquisition systems. Prior to our study, it was
evident that iron is required for growth and virulence of B. pertussis. One of the factors
that could account for this difference is that the SSM broth is rich in iron to allow
optimal growth of the pathogen (37). B. pertussis is hemolytic due to ACT (38), which
would lead to lysis of red blood cells, facilitating heme uptake (39). We also observed
pertussis toxin and secretion genes to be highly expressed (Fig. 5A); but these data are
not surprising because PT is a critical virulence factor for B. pertussis, and it is controlled
by the BvgAS system as a virulent-phase gene (40). Also, it is not surprising to see iron
acquisition upregulated in correlation with virulence gene expression since iron is an
essential element that pathogens need for infection. On the other hand, we had
expected that ACT would also be more highly expressed in vivo, but its expression
during infection was not different from that in in vitro SSM growth. The type III secretion
system of B. pertussis has been shown to be active in clinical isolates (41), and
expression of the effector protein Bsp22 has been detected during the course of mouse
infection (42). We observed many genes associated with the type III section system to
be highly expressed in vivo during murine infection (Fig. 4). The btrA and brpL genes
FIG 6 B. pertussis activates expression of iron acquisition systems in vivo. (A to C) A model representing B. pertussis alcaligin, enterobactin, and heme acquisition
systems. OM/IM, outer/inner membrane. (D) B. pertussis iron and heme acquisition systems highly expressed in vivo compared to expression in vitro. Yellow
denotes highly expressed B. pertussis alcaligin acquisition system genes, green denotes highly expressed enterobactin acquisition system genes, and white
represents highly expressed heme acquisition system genes.
Wong et al.
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encode an anti-sigma factor and sigma factor system that control expression of the
type III secretion system (24), and we also observed high expression of these genes in
vivo (see Table S1 in the supplemental material). All together, these data suggest that
that the type III secretion system is more highly expressed in vivo than in vitro.
van Beek and colleagues used RNA amplification and microarray analysis to deter-
mine in vivo gene expression of B. pertussis strains B1917 and B1920 in 6- to 8-week-old
BALB/c mice (28). In their studies, bacteria were isolated at 7 days postchallenge from
the nasal and bronchoalveolar lavages. The study revealed enhanced gene expression
of fimbrial adhesion genes, type III secretion system genes, btrA and brpL (anti-sigma
and sigma factor), pertussis toxin, dermonecrotic toxin, and other genes. Due to the
differences in detection technologies (microarray and RNA-seq), we did not directly
compare the relative gene expression fold changes, but we correlated gene expression
as activated or repressed between the two data sets. When we compare our study to
that of van Beek et al., we see strong correlations with several key differences. We found
111 genes to be commonly activated in both sets of data, and these included the
virulence factors already described above, as well as many hypothetical genes (Ta-
ble S1). There were 16 commonly repressed genes in vivo, which included the cysteine
operon. The cysAWTP genes encode proteins involved in sulfate/thiosulfate import.
When our activated in vivo gene expression list was compared to the activated gene
expression list of van Beek et al., there was a noticeable set of genes that were different,
and most corresponded to iron acquisition genes. For in vitro cultures, van Beek et al.
used THIJS medium (43) which has a similar amount of supplemented iron as SSM but
different nitrogen and carbon ratios. In addition to use of a slightly different liquid
broth growth medium, 0.2 mg/ml heptakis-cyclodextrin was supplemented to enhance
growth. Heptakis is added to liquid growth medium to ameliorate the effects of fatty
acids on the growth of B. pertussis (44–48). For our growth conditions, we utilized fresh,
never-used glassware, which negates the need to add heptakis to stimulate growth
(unpublished observation). Other differences between these two studies are the mouse
strains (NSG versus BALB/c) and challenge strains of B. pertussis that were used. We used
NSG mice in order to get sufficient amounts of bacteria for RNA-seq. It is possible that
these aforementioned experimental design differences account for the differences
between results of the in vivomicroarray and our in vivo RNA-seq study. Overall, the two
studies agree in the majority of observations and advance our knowledge of the
infection transcriptome of B. pertussis.
In this study, we infected NSG mice to achieve a higher bacterial burden in the lungs
to characterize the infection transcriptome of B. pertussis using RNA-seq. By using NSG
mice, we subjected B. pertussis to an immune environment lacking mature lympho-
cytes, functional macrophages, and dendritic cells. The absence of these cells could
change the transcriptome of B. pertussis during infection because the bacteria are not
encountering immune effector mechanisms to clear the infection, thus potentially
changing the activation and repression of certain virulence factors. This is a caveat of
our study, and in the future, we will aim to perform in vivo RNA-seq in immunocom-
petent mice once we overcome several technical hurdles. Another caveat that should
be considered is the high bacterial burden. It is not likely that B. pertussis grows to high
density within the human host; therefore, bacterial cell density could affect total gene
expression, and future studies will aim to analyze smaller populations of B. pertussis
from the host.
In vivo RNA-seq is in its early stages of development, and as of the writing of the
manuscript, there are approximately 20 total publications that have profiled the
transcriptomes of bacteria during infection of host animals or host cells (49). All in vivo
RNA-seq projects must overcome the low abundance of pathogen RNA due to the large
amounts of host RNA (49, 50). In a recent RNA-seq analysis of Yersinia
pseudotuberculosis-infected mouse Peyer’s patches, only 0.2 to 1.4% of reads corre-
sponded to pathogen RNA. Despite that small amount of RNA read data, important
observations were made concerning Yersinia pathogenesis (51). At the onset of our
study, we aimed to map the in vivo transcriptome of B. pertussis in the murine host
In Vivo RNA-seq Analysis of B. pertussis
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using RNA-seq. While we were able to overcome the hurdle of isolating bacteria from
the infected lung, we still managed to retain a large amount of RNA from the host (98
to 99% of the read data). Remarkably, the majority of the host RNA corresponds to
mitochondrial RNA (data not shown). During filtration, we hypothesize that the small
size of mitochondria allowed them to flow through the filter. We filtered mouse lungs
with the 5-m-pore-size filter and used microscopy to observe that mitochondria were
in high abundance in the lung filtrate (data not shown). While RNA-seq provided us
with sufficient data to describe a strong draft transcriptome, we now aim to advance
toward determining gene expression from smaller populations of B. pertussis in the
respiratory tract. We hypothesize there are multiple populations in any infected host,
such as Bvg, Bvg, and Bvgi B. pertussis. One caveat of our approach is that some
bacteria do not go through the filter. We are able to increase our total recovery by
flushing more phosphate-buffered saline (PBS) through the filter. But it is likely that the
bacteria that do not pass through the filter are in microcolonies or are attached to cells.
In order to characterize these populations, we will need to develop protocols to isolate
small populations of bacteria with extremely minimal amounts of host RNA contami-
nation. We ultimately want to develop a protocol and work flow that would allow for
analysis of strains directly from infected patients or other model organisms. Our future
studies will also aim to utilize immunocompetent hosts to observe the effects of the
innate and adaptive immune systems on B. pertussis during infection. There are several
technologies for eukaryotic cells that allow for single-cell RNA-seq analysis (52). A
significant amount of protocol development will need to occur for that to be possible
for bacteria. We envision that in the coming decade single-cell bacterial RNA-seq will
become the standard, and it will be interesting to compare single-cell data to data
reflecting the average of all infecting bacteria, such as the data set we present in this
study. It is possible that there are bacteria in different phases of virulence, but
technological improvements in the work flow are still required. As we learn more about
what these pathogens are expressing during infection, it is likely that new antigens that
were previously not identified could be exploited for vaccine development. In the near
future, it may be possible to isolate pathogens directly from human patients and
determine the human-specific and phase-specific (initial infecting or transmitting)
transcriptomes of the pathogen. We aim to fully characterize the transcriptome of the
human pathogen B. pertussis and to use in vivo RNA-seq to enhance our knowledge of
how pathogens infect their hosts.
MATERIALS AND METHODS
Bacterial strains and growth conditions. B. pertussis strain UT25 (UT25Sm1) (53) was cultured on
Bordet-Gengou (BG) agar (Remel) (54) supplemented with 15% defibrinated sheep blood (Hemostat
Laboratories) for 48 h at 36°C. B. pertussis was then transferred from BG plates to three flasks containing
12 ml of modified Stainer-Scholte liquid medium (SSM) (37). SSM cultures were not supplemented with
cyclodextrin [heptakis(2,6-di-O-methyl)--cyclodextrin)] and were grown for 22 h at 36°C with shaking
at 180 rpm until the optical density at 600 nm (OD600) reached 0.5 on a 1-cm-path-width spectropho-
tometer (DU 530; Beckman Coulter). For infection of NSG mice, cultures were then diluted to provide a
challenge dose of 2 107 CFU in 20 l. For growth of Pseudomonas aeruginosa strain PAO1, Pseudomo-
nas Isolation Agar (Difco) was used. Bordetella bronchiseptica RB50 and Escherichia coli TOP10 were
cultured on lysogeny agar (10 g of NaCl, 5 g of yeast extract, 10 g of tryptone) at 36°C for 18 h. In vitro
cultures of bacteria were grown and then filtered through 5-m-pore-size syringe filters (Minisart;
Sartorius). The total number of input and output bacteria were determined through serial dilutions and
plate counts on the appropriate medium, and the percent recovery of each species was determined.
Murine B. pertussis challenge. NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, stock number 005557;
Jackson Laboratory) were raised in-house by the West Virginia University (WVU) Transgenic Animal Core
Facility. Mice were anesthetized by intraperitoneal injection of ketamine and xylazine in saline according
to approved protocols. Two 10-l doses of B. pertussis were pipetted directly into each nostril of the
mouse to provide a challenge dose of 2 107 CFU in 20 l. Five to seven mice were infected with strain
UT25, and mice were euthanized by pentobarbital injection 3 days postchallenge. All murine infection
experiments were performed according to protocols approved by the West Virginia University Institu-
tional Animal Care and Use Committee (IACUC; protocol numbers 14-1211 and 1602000797), conforming
to AAALAC accreditation guidelines.
Isolation of B. pertussis from infected NSG lungs. Lungs were extracted and quickly homogenized
in a sterile Dounce glass homogenizer. A sample of the homogenate was used to determine total
bacterial burden by performing serial dilutions in PBS that were then plated on BG medium containing
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streptomycin (100 g/ml). The rest of the homogenate was passed through a 70-m-pore-size cell
strainer (VWR), and then the filtrate was passed through a 5-m-pore-size filter (Minisart type 17594
cellulose acetate; Sartorius) via a syringe. A sample of the final filtrate was used to determine the number
of bacteria recovered. The filtrate was then centrifuged (4°C at 16,100 g) to pellet the bacteria. The
supernatant was removed, and 200 l of bacterial RNAprotect was added to the pellet. The pellet was
resuspended and then pelleted by centrifugation for 2 min at 16,100 g. The pellet was then frozen at
80°C until RNA isolation.
RNA isolation. One B. pertussis-infected NSG mouse was used per biological sample for RNA-seq.
RNAsnap lysis was used to isolate RNA from the filtered B. pertussis cells from the infected murine lungs
(55). Cell pellets were resuspended in RNAsnap extraction solution (18 mM EDTA, 0.025% SDS, 1%
-mercaptoethanol, 95% formamide) by vortexing vigorously. Samples were incubated at 95°C for 7 min
and pelleted by centrifugation at 16,100 g for 5 min at room temperature. The supernatant containing
RNA was then pipetted into a fresh tube without disturbing the clear gelatinous pellet, and DNA and RNA
concentrations were measured using a Qubit 3.0 fluorometer (ThermoFisher). The resulting RNA was
treated with RNase-free DNase (Qiagen). To remove the DNase, the samples were then cleaned up on an
RNeasy Mini column (Qiagen). The resulting RNA was quantified on a Qubit 3.0 fluorometer. To ensure
that RNA was DNA free, 25 ng of RNA was checked by quantitative PCR (qPCR) amplification as described
below and was used only for cDNA if the threshold cycle (CT) was 30. The following primers were used
for the DNA-free confirmation: mouse gapdh-F (CATGGCCTTCCGTGTTCCT), mouse gapdh-r (GCGGCAC
GTCAGATCCA) and fhaBF/fhaBR (25). The RNA integrity was assessed by running the samples on an
Agilent BioAnalyzer RNA Pico chip. To compare in vitro to in vivo samples, B. pertussis was cultured in SSM
broth, and bacterial RNA was isolated with RNAsnap. The RNA was subjected to DNase treatment
(Qiagen), and cleanup procedures were performed as described above.
qRT-PCR. For quantitative reverse transcription-PCR (qRT-PCR) analysis, cells stored at 80°C in
RNAprotect (Qiagen) were lysed using the RNAsnap method as described above (55). To ensure that RNA
was DNA free, 25 ng of RNA was checked by qPCR amplification as described below and was used only
for cDNA if no amplicon was observed and if the CT value was 30 using the fhaBF and fhaBR primers.
cDNA was synthesized using Moloney murine leukemia virus (M-MLV) reverse transcriptase (Promega)
per the manufacturer’s instructions using 200 ng of RNA and gene-specific reverse primers for targets.
Twenty-five microliter qPCRs were set up with Excella SYBR Green PCR master mix (Worldwide Medical
Products), per the manufacturer’s instructions, using 1 l of cDNA that was generated from 500 ng of
RNA. A minimum of three technical replicate reactions were run per gene target per sample on a Step
One Plus qPCR thermocycler (Applied Biosystems). Primers were designed on Primer3 (Primer-BLAST;
NCBI) and checked for specificity by PCR. Melt curve analysis as well as subsequent agarose gel
electrophoresis was performed on all reaction products. Gene expression was normalized to that of the
rpoB reference using the 2ΔΔCT method (56). For statistical analysis, the ΔCT for the three biological
replicate experiments was calculated, and a Student’s t test was performed. Standard error of mean was
calculated based on the variability of the ΔCT value of three biological replicates. The following primer
sequences used in this study were described by Bibova et al. (57): cyaF (CGAGGCGGTCAAGGTGAT), cyaR
(GCGGAAGTTGGACAGATGC), ptxAF (CCAGAACGGATTCACGGC), ptxAR (CTGCTGCTGGTGGAGACGA), bv-
gAF (AGGTCATCAATGCCGCCA), bvgAR (GCAGGACGGTCAGTTCGC), fhaBF (CAAGGGCGGCAAGGTGA),
fhaBR (ACAGGATGGCGAACAGGCT), rpoBF (GCTGGGACCCGAGGAAAT), and rpoBR (CGCCAATGTAGACG
ATGCC). Primers for the amplification of BP2497 were also designed in a previous study: BP2497F
(TCGGATCGCACCAATTACTTC) and BP2497R (CCTTGGCGATCAGCGAGTT) (25). The following primers were
used for glyceraldehyde-3-phosphate dehydrogenase (GAPDH): gapdhf (CATGGCCTTCCGTGTTCCT) and
gapdhr (GCGGCACGTCAGATCCA).
Library construction and Illumina sequencing. In vitro and in vivo RNA samples were subjected to
both bacterial and murine RiboMinus Transcriptome Isolation kits (ThermoFisher), in order to deplete
rRNA. The RNA depleted of rRNA was then converted into Illumina sequencing libraries with a SMART-
Seq, version 4, low-input kit (Clontech). Resulting libraries passed standard Illumina quality control PCR
and were sequenced on an Illumina Hiseq 4000 at Admera Health (South Plainfield, NJ). A total of 90 to
100 million 2- by 150-bp reads were devoted to each sample, both in vitro and in vivo.
RNA-seq and bioinformatics analyses. The reads were aligned to the B. pertussis Tohama I genome
(58) using CLC Genomics Workbench, version 9.5 (Qiagen). Table S1 in the supplemental material
contains the gene expression data obtained for this project. The number of reads per kilobase per million
(RPKM) and fold change for each gene were calculated. Fold change was calculated by comparison of the
number of in vitro UT25 B. pertussis reads to the number of in vivo NSG mouse UT25 reads. Based on the
number of reads mapped to the genome of UT25 in vivo, we down-sampled the total in vitro reads to
1 million 2- by 150-bp reads to compare similar numbers of reads between the in vitro and in vivo data
sets. Down-sampling was performed in CLC Genomics, version 9.5 (Qiagen), utilizing the random output,
which returns a random sample of the reads, resulting in an equal distribution to the original total read
data set. An empirical analysis of digital gene expression (EDGE) was performed to determine differen-
tially expressed genes (59). Genes with an EDGE test P value of 0.05 were considered differentially
regulated. Genes were annotated with custom Gene Ontology Annotation (GOA) files that were created
from annotations downloaded from UniProt (proteome identification number UP000002676). Subsets of
statistically significant genes were compared to the total genes of the genome to identify GOA terms that
were enriched using a HyperG test and to determine the most common and active biological processes,
cellular components, and molecular functions in the experiment (60). A volcano plot was created by
plotting significant genes using their EDGE test fold change values and the negative log of their EDGE
test P values (59). The STRING functional protein association networks database (61) was used to
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associate systems of genes in order to create a heat map visualization for activated and repressed in vivo
genes.
Accession number(s). The mapped reads are available at the Sequence Read Archive (SRA) under
BioProject accession number PRJNA433887 and SRA accession number SRX3691783.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
mSphereDirect.00154-19.
TABLE S1, XLSX file, 2.8 MB.
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